1、 曹焱, 潘慧丽, 张超. PD-1靶向性肿瘤治疗抗体药物在消化道肿瘤中的应用价值[J]. 实用癌症杂志, 2018, 33(8):1330-1332. 曹焱, 潘慧丽, 张超. PD-1靶向性肿瘤治疗抗体药物在消化道肿瘤中的应用价值[J]. 实用癌症杂志, 2018, 33(8):1330-1332.
2、 蔡正平, 辜军, 蔡雯. 恶性肿瘤特异性生长因子对恶性肿瘤的诊断价值[J]. 中国肿瘤临床与康复, 2018, 25(5):46-48. 蔡正平, 辜军, 蔡雯. 恶性肿瘤特异性生长因子对恶性肿瘤的诊断价值[J]. 中国肿瘤临床与康复, 2018, 25(5):46-48.
3、 雷永付. 血清CEA, CA72-4,CA19-9,PG Ⅰ/PG Ⅱ和AFP联合检测用于食管癌早期诊断的价值分析[J]. 标记免疫分析与临床, 2020, 27(4):124-126,167. 雷永付. 血清CEA, CA72-4,CA19-9,PG Ⅰ/PG Ⅱ和AFP联合检测用于食管癌早期诊断的价值分析[J]. 标记免疫分析与临床, 2020, 27(4):124-126,167.
4、 温东辉. 癌胚抗原,甲胎蛋白,糖类抗原199和糖类抗原联合检测在食管癌诊断中的应用分析72-[J]. 黑龙江医学, 2020, 44(3):83-84. 温东辉. 癌胚抗原,甲胎蛋白,糖类抗原199和糖类抗原联合检测在食管癌诊断中的应用分析72-[J]. 黑龙江医学, 2020, 44(3):83-84.
5、 德庆旺姆, 金璿, 赵玉兰,等. PD-1单抗单药或联合治疗在西藏地区藏族晚期恶性肿瘤患者中的疗效和安全性[J]. 西藏医药, 2020, 41(5):75-78. 德庆旺姆, 金璿, 赵玉兰,等. PD-1单抗单药或联合治疗在西藏地区藏族晚期恶性肿瘤患者中的疗效和安全性[J]. 西藏医药, 2020, 41(5):75-78.
6、 朱丹, 李月阳, 宋燕青,等. PD-1抑制剂信迪利单抗的临床研究进展[J]. 中国医院药学杂志, 2020, 40(1):120-123. 朱丹, 李月阳, 宋燕青,等. PD-1抑制剂信迪利单抗的临床研究进展[J]. 中国医院药学杂志, 2020, 40(1):120-123.
7、 ZHANG L, MAI W Q, JIANG W Y,et al. Sintilimab: a promising anti-tumor PD-1 antibody[J]. Front Oncol,2020(10):594558. ZHANG L, MAI W Q, JIANG W Y,et al. Sintilimab: a promising anti-tumor PD-1 antibody[J]. Front Oncol,2020(10):594558.
8、 MA S Z, DANG Q, YANG Y L,et al. Sintilimab, a PD-1 inhibitor, completely reversed rarely refractory hypofibrinogenemia in a gastric cancer patient: a case report and review of the literature[J]. Front Oncol,2020 (10):526096. MA S Z, DANG Q, YANG Y L,et al. Sintilimab, a PD-1 inhibitor, completely reversed rarely refractory hypofibrinogenemia in a gastric cancer patient: a case report and review of the literature[J]. Front Oncol,2020 (10):526096.
9、 LIAO Z W, LV X W, HE Z F,et al. Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/T-CL[J]. Asia-Pac J Clin Oncol,2018,14(5):e252-e258. LIAO Z W, LV X W, HE Z F,et al. Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/T-CL[J]. Asia-Pac J Clin Oncol,2018,14(5):e252-e258.
10、 MISHRA A K, KADIOSHI T, WANG X G,et al. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T cells co-expressing PD-1 and LAG-3 inhibitory receptors[J]. Oncotarget, 2016,7(49):61341-81356. MISHRA A K, KADIOSHI T, WANG X G,et al. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T cells co-expressing PD-1 and LAG-3 inhibitory receptors[J]. Oncotarget, 2016,7(49):61341-81356.
11、 GAO S G, LI N, GAO S Y,et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in non-small cell lung cancer[J].J Thorac Oncol,2020,15(5):816-826. GAO S G, LI N, GAO S Y,et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in non-small cell lung cancer[J].J Thorac Oncol,2020,15(5):816-826.
12、 SOHDA M,KUWANO H. Current status and future prospects for esophageal cancer treatment[J]. Ann Thorac Cariovasc Surg,2017,23(1):1-11. SOHDA M,KUWANO H. Current status and future prospects for esophageal cancer treatment[J]. Ann Thorac Cariovasc Surg,2017,23(1):1-11.
13、 马晓斌, 务森, 闫曼曼,等. 局部进展期食管癌患者围术期化疗后复发转移临床分析[J]. 中华实用诊断与治疗杂志. 2020, 34(4):56-59. 马晓斌, 务森, 闫曼曼,等. 局部进展期食管癌患者围术期化疗后复发转移临床分析[J]. 中华实用诊断与治疗杂志. 2020, 34(4):56-59.
14、 WATANABE M, OTAKE R, KOZUKI R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer[J]. Surgery Today,2020,50(1):12-20. WATANABE M, OTAKE R, KOZUKI R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer[J]. Surgery Today,2020,50(1):12-20.
15、 HUANG F L,YU S J.Esophageal cancer: risk factors, genetic association, and treatment[J]. Asian J Surgery, 2018,41(3):210-215. HUANG F L,YU S J.Esophageal cancer: risk factors, genetic association, and treatment[J]. Asian J Surgery, 2018,41(3):210-215.
